Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation - Wikidata - awgldk - TriplyDB

Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation

Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation

http://www.wikidata.org/entity/Q36444987

about

Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog Mechanisms of cardiac arrhythmias Synchronization of chaotic early afterdepolarizations in the genesis of cardiac arrhythmias.Mechanisms of stretch-induced atrial fibrillation in the presence and the absence of adrenocholinergic stimulation: interplay between rotors and focal discharges.Short QT syndrome: from bench to bedside.Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.Genesis of phase 3 early afterdepolarizations and triggered activity in acquired long-QT syndrome.Overview of Basic Mechanisms of Cardiac Arrhythmia Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations.Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation Novel pharmacological targets for the rhythm control management of atrial fibrillation.Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations.Electrophysiological characteristics of canine superior vena cava sleeve preparations: effect of ranolazine.Triggered firing and atrial fibrillation in transgenic mice with selective atrial fibrosis induced by overexpression of TGF-β1.Reduction in Kv Current Enhances the Temporal Dispersion of the Action Potential in Diabetic Myocytes: Insights From a Novel Repolarization Algorithm.Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations.Early afterdepolarizations in cardiac myocytes: beyond reduced repolarization reserve Fever accentuates transmural dispersion of repolarization and facilitates development of early afterdepolarizations and torsade de pointes under long-QT Conditions.Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation.Atrial-selective sodium channel blockers: do they exist?Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations Mutation E169K in junctophilin-2 causes atrial fibrillation due to impaired RyR2 stabilization.Dynamics of the late Na(+) current during cardiac action potential and its contribution to afterdepolarizations.Atrial-selective sodium channel block for the treatment of atrial fibrillation.Altered Excitation-Contraction Coupling in Human Chronic Atrial Fibrillation.New pharmacological strategies for the treatment of atrial fibrillation New developments in atrial antiarrhythmic drug therapy.The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications.Supplemental studies for cardiovascular risk assessment in safety pharmacology: a critical overview.Do t-tubules play a role in arrhythmogenesis in cardiac ventricular myocytes?New antiarrhythmic targets to control intracellular calcium handling.Pulmonary Vein Sleeves as a Pharmacologic Model for the Study of Atrial Fibrillation.Ca²⁺-induced delayed afterdepolarizations are triggered by dyadic subspace Ca2²⁺ affirming that increasing SERCA reduces aftercontractions.Atrial metabolism and tissue perfusion as determinants of electrical and structural remodelling in atrial fibrillation.How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation?Mathematical simulations of ligand-gated and cell-type specific effects on the action potential of human atrium.How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation?The action potential of the Purkinje fiber: an in vitro model for evaluation of the proarrhythmic potential of cardiac and noncardiac drugs.

P2860

Q24601144-2B3CCC64-69F9-4FAE-B1C5-E590CEF35FA3 Q24607775-A6558608-525C-4D7C-BD02-983EE09A4E9B Q26752476-3F3A986C-A699-4215-AF0C-674A5107BF26 Q30486315-DAE77B37-B05D-4406-8837-9E04ECEB88BE Q30494264-302DF2D5-8079-450E-BE73-66EA71F74DE8 Q34102891-EC9D5CAC-145E-4F9A-AD73-9CF38FABDCA4 Q34181734-23B75BCF-1F17-4168-8E2D-6853BCDBE48C Q34607621-FF902708-89E0-4236-9F82-AFBB12D9022D Q34632042-AA61F03D-7F33-40B9-9D99-A7200137AD42 Q34682939-87DC2564-26B8-4D73-BC32-485D0EEA33AE Q34700436-C38C4E86-C55F-4E6F-83DB-B19EBA1B1D49 Q34765700-95B661FB-FDAA-452A-8668-478747C54672 Q35489060-DABAB690-5242-494E-8B6D-DA59B2FDE8B7 Q35785780-39FBCC54-818D-45EC-B786-942FA9464DF5 Q35897540-E29ADE5C-9C43-4896-A800-ABE59DE3794A Q36671389-EC849C6C-0664-4F72-AD5B-01BD502F6EA5 Q36714022-485D9AB9-28B7-479E-A191-B56E33D40BC1 Q36839147-06D941BC-1E40-4172-B161-5BCDDBC8A836 Q36943422-D2CFAEEA-C8C3-4BE0-987E-16E15C9713C1 Q37011111-165AA74B-D951-454B-A6ED-B861A49FD120 Q37093085-399B61B3-0FF6-4EBA-BB9A-F3B350D1EE28 Q37231700-39D163B1-45F4-4289-B707-225C3B272B8F Q37315220-2A3C53A2-8FB3-492C-888D-2837DA29969C Q37315854-D50F1C13-2865-4DA4-BE38-F971185601CF Q37377307-8CA92237-05BD-45B1-9D4C-3B64F3688B29 Q37494653-AA0395AA-5382-493F-B908-0719D9032BF6 Q37496226-8FF67084-948E-4F55-B0A5-0528B75D857E Q37554693-22B2E717-1D56-488D-BA30-AC0EC998C130 Q37697498-181C1607-84C1-49D3-AEBA-347CCAF8568D Q37799958-524C8234-9409-41C7-B70E-166A11D5FF26 Q37909132-AF1B5885-5F22-49C7-9ABB-61FBAE5B14BF Q38104947-53D67C5B-EC4F-4678-9E70-340EA9E698D3 Q38204723-17770779-56A2-4B5E-BFE5-12A94230BF73 Q38226807-9982535F-000E-4EEB-8B62-B0071980C368 Q38677208-9AA1ACE5-AFEC-4E68-A5E6-87F11131D3BA Q38703115-B5BF3AA3-FD53-482C-A82E-E0830A2C1A06 Q38790685-FB2C1840-9A35-465D-9B61-F39C226DA993 Q39568164-60736B56-CB75-4603-8F94-2D5AEDF4D76B Q42385429-1EF8E03A-6976-46A3-A986-5D45B0C9385F Q42721783-05007D61-802E-4BDF-9EC5-F0378ECD32B6

P2860

Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation

http://www.wikidata.org/entity/Q36444987

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation

@ast

Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation

@en

type

label

Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation

@ast

Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation

@en

prefLabel

Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation

@ast

Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation

@en

P1433

Q36444987-C59D0BEA-5156-40CE-B420-C06B49BCB83A

P1476

Q36444987-A4274290-4229-46E9-9D87-806BC383E711

P2093

Q36444987-CFD34EA2-B2E5-4A42-A1F8-68B86EA17947

P2860

Q36444987-05345561-B865-4F3F-A08D-FB896C2DA8C2

Q36444987-0C1317A8-D636-4705-86DF-FC7E03945BEE

Q36444987-0F164721-3002-40CD-B18C-FD09457C24BB

Q36444987-11F66562-045E-4E14-8705-22055D506131

Q36444987-132C8E70-1F5B-4EE6-A718-6146FB665E2B

Q36444987-2784E602-9ED3-4ADB-A184-F66F7BAAED05

Q36444987-5FF51CC4-68BD-49F0-A23A-1B14EFB04C78

Q36444987-647A73DB-B071-498B-86DD-A00098618470

Q36444987-6CA6224D-C8E5-4854-8511-A563BE0E2309

Q36444987-83107CA9-8DA9-409B-875C-10F46FD7CA67

P304

Q36444987-E5CB6899-0DE4-4B95-9450-4B40A8D425E8

P31

Q36444987-EAF0FB24-ED8C-4957-99A5-D760DAF39EC4

P356

Q36444987-8E4C6072-FBD4-40DB-A52B-747C2C6F9507

P433

Q36444987-9D0AEEC3-E216-4D9A-A5E2-F86278F5F0C7

P478

Q36444987-FFC635BF-A548-4084-BBB5-4AD24369E9D8

P50

Q36444987-3CEB9C6F-0A7F-41E4-A72A-75B25693ACA1

Q36444987-ADFEA4F6-3234-4A7F-A6EE-BD185966D465

P577

Q36444987-2C1600EC-26F6-4AEB-9013-0C08CA4EBFF1

P5875

Q36444987-0912BBD8-9656-48D4-86A7-7E661BAF123C

P698

Q36444987-AFBE7E57-FA3E-42B7-8B6D-7D28BCCC7A50

P921

Q36444987-0C3221BD-E755-4E28-9C7A-D3001F4AB864

P932

Q36444987-2ABFE8AC-AAEE-468B-918E-6A9211486C67

P356

J.1540-8159.2006.00336.X

P1433

Pacing and Clinical Electrophysiology

P1476

Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation

@en

P2093

Alexander Burashnikov

http://www.w3.org/2001/XMLSchema#string

P2860

Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins

Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts.

Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes. A weaker IKs contributes to the longer action potential of the M cell.

Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes.

Effects of rapid atrial pacing on the arrhythmogenic activity of single cardiomyocytes from pulmonary veins: implication in initiation of atrial fibrillation.

Prominent I(Ks) in epicardium and endocardium contributes to development of transmural dispersion of repolarization but protects against development of early afterdepolarizations.

ENaC plays a role in regulated antibody secretion by hybridomas.

Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity.

Transmembrane action potential heterogeneity in the canine isolated arterially perfused right atrium: effect of IKr and IKur/Ito block.

Nonreentrant focal activations in pulmonary veins in canine model of sustained atrial fibrillation.

P304

290-295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1540-8159.2006.00336.X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Charles Antzelevitch

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7174388

http://www.w3.org/2001/XMLSchema#string

P698

16606397

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation

P932

1474077

http://www.w3.org/2001/XMLSchema#string